Serotonin Norepinephrine Reuptake Inhibitor Is Associated With Lower Mortality Among Patients Presenting With...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed for depression and neuropathic pain.
• Their impact on Takotsubo cardiomyopathy (TCM) clinical outcomes remains under investigation.

Purpose of the Study:

• To evaluate the effect of SNRIs on mortality and TCM-related complications.
• To assess the safety and efficacy of SNRIs in patients diagnosed with TCM.

Main Methods:

• Retrospective analysis of the TriNetX research network data (2003-2023).
• Inclusion of patients aged ≥18 with a primary TCM diagnosis.
• Exclusion of patients on specific medications and with confounding conditions.
• Propensity score matching to compare outcomes between SNRI users and non-users.

Main Results:

• 16,853 TCM patients identified; 14.7% used SNRIs.
• SNRI users were slightly older.
• Post-matching, SNRI use was associated with significantly lower 7-day mortality (OR 0.59), cardiac arrest (OR 0.58), and ventricular fibrillation (OR 0.496).
• One-year mortality was also lower in the SNRI group (OR 0.80).

Conclusions:

• SNRI use in TCM patients is associated with reduced all-cause mortality.
• SNRIs may also decrease the incidence of TCM-related complications.